{"id":928244,"date":"2026-01-16T16:13:59","date_gmt":"2026-01-16T21:13:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"},"modified":"2026-01-16T16:13:59","modified_gmt":"2026-01-16T21:13:59","slug":"xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","title":{"rendered":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>VANCOUVER, British Columbia and BOSTON, Jan.  16, 2026  (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company\u2019s Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The share options have an exercise price of\u00a0$40.74 per common share, which is equal to the closing price per share of Xenon\u2019s common shares on the grant date of\u00a0January 15, 2026. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee\u2019s start date and 1\/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient\u2019s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company\u2019s Amended and Restated 2025 Inducement Equity Incentive Plan.<\/p>\n<p>\n        <strong><br \/>\n          <u>About Xenon Pharmaceuticals Inc.<br \/><\/u><br \/>\n        <\/strong>Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon\u2019s lead molecule, azetukalner, is a novel, potent K<sub>V<\/sub>7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K<sub>V<\/sub>7 and Na<sub>V<\/sub>1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=irIfmCLUl9beu_6VBJDHInYDCrPAZu4G6_9iH3MNAsyyo1Hn9F5rRBlqdsZUsAIjb6jCpsKs1aDBLffNjJ5uDfW3S4ocSDAikwz4X5eDcM8=\" rel=\"nofollow\" target=\"_blank\">www.xenon-pharma.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1_K8lcFFFhuQPZpBdHOat5nPjkj1HWfABYohXqr7DeQFqTbzDTz2e9WZP-1tMVc6LkHb9uBRql8Llzvjq_xN6M0yOtMTtlbapAbEuDm8x-o=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FBYoG2yxx3p5EjjZzm3YoEjUr-yPLvv1DdNSFBcVykOkpI2coirYUGwttBcONxmALMS6a4FHX-sfNPZCyjec5w==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contacts<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <em>For Investors:<\/em><br \/>\n        <br \/>Tucker Kelly<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gOGvy9lsl4HvsOtCGWItuc_70fj4gkrjmNtpESOjXBbkVB_BKIzS6sJdH4-6qlfvO2QIoCamJ7-OO0yRiEaitAW_C8iGaUd8WGHf_7bJzsNu4YreTNoe0D58NRreagUa\" rel=\"nofollow\" target=\"_blank\">investors@xenon-pharma.com<\/a><\/p>\n<p>\n        <em>For Media:<\/em><br \/>\n        <br \/>Colleen Alabiso<br \/>Senior Vice President, Corporate Affairs<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kmkX4ZLbvFtQhNKbdpNAjPWP4lTjtStnSoNQYmXxzwODIO2TR6BxmLxY4tp-AJaopbMUvv2K6HQHTv7M8scxiSme9dfo4K9vBKuiW8chAEw=\" rel=\"nofollow\" target=\"_blank\">media@xenon-pharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzQ2N2IzYjgtOTdiYS00NTIwLTkzYTctMjA0NGFiOTkwYWNlLTEwMjI5NTMtMjAyNi0wMS0xNi1lbg==\/tiny\/Xenon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company\u2019s Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of\u00a0$40.74 per common share, which is equal to the closing price per &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928244","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company\u2019s Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of\u00a0$40.74 per common share, which is equal to the closing price per &hellip; Continue reading &quot;Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T21:13:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-01-16T21:13:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\"},\"wordCount\":380,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\",\"name\":\"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=\",\"datePublished\":\"2026-01-16T21:13:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","og_locale":"en_US","og_type":"article","og_title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company\u2019s Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of\u00a0$40.74 per common share, which is equal to the closing price per &hellip; Continue reading \"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-16T21:13:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-01-16T21:13:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"},"wordCount":380,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","name":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=","datePublished":"2026-01-16T21:13:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNzM1OCM3MzY2MTQ5IzIwMTEzODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928244"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928244\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}